Clinical Trials Logo

Filter by:
NCT ID: NCT00354094 Terminated - Pain Clinical Trials

[S,S]-Reboxetine Long Term Safety Study In Post-Shingles Pain.

Start date: November 2006
Phase: Phase 2
Study type: Interventional

The purpose of this study is to assess the long term (up to 2 years) safety and tolerability of [S,S]-Reboxetine in patients with pain after shingles.

NCT ID: NCT00353574 Terminated - Hypertension Clinical Trials

DORADO-EX: Long-Term Safety Extension Study to the Phase 3 DORADO Study (Protocol DAR-311) of Darusentan in Resistant Hypertension

Darusentan
Start date: September 2006
Phase: Phase 3
Study type: Interventional

This is a research study of a new experimental drug called darusentan. Darusentan is not currently approved by the United States (U.S.) Food and Drug Administration (FDA) for use in the U.S., which means that a doctor cannot prescribe this drug. The purpose of this study is to evaluate the long-term safety of darusentan in subjects with resistant systolic hypertension despite treatment with full doses of three or more antihypertensive medications, including a diuretic.

NCT ID: NCT00352079 Terminated - Bladder Cancer Clinical Trials

BCG With or Without Gefitinib in Treating Patients With High-Risk Bladder Cancer

Start date: January 4, 2007
Phase: Phase 3
Study type: Interventional

RATIONALE: Biological therapies, such as BCG, may stimulate the immune system in different ways and stop tumor cells from growing. Gefitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving BCG together with gefitinib may kill more tumor cells. It is not yet known whether BCG is more effective with or without gefitinib in treating bladder cancer. PURPOSE: This randomized phase III trial is studying BCG and gefitinib to see how well they work compared to BCG alone in treating patients with high-risk bladder cancer.

NCT ID: NCT00351715 Terminated - Pain Clinical Trials

Sublingual Methadone for the Management of Cancer-related Breakthrough Pain in Outpatients

Start date: July 2008
Phase: Phase 2
Study type: Interventional

The purpose of this Phase II study is to determine the feasibility of the dose titration and assessment protocol in the outpatient population before conducting an appropriately powered phase III study. Thus the primary purpose of this study is to determine the proportion of patients who are successfully titrated to an optimal dose of sublingual (Under the tongue) methadone and then studied at that optimal dose with successive episodes of breakthrough pain.

NCT ID: NCT00351637 Terminated - Pain Clinical Trials

Sublingual Methadone for the Management of Cancer-related Procedure Pain in Inpatients

Start date: December 2006
Phase: Phase 2
Study type: Interventional

The purpose of this Phase II study is to determine the feasibility of the dose titration and assessment protocol in the impatient population, in the clinical setting of preventing or managing breakthrough pain, before conducting an appropriately powered phase III study. Thus the primary purpose of this study is to determine the proportion of patients who are successfully titrated to an effective dose of sublingual methadone.

NCT ID: NCT00351364 Terminated - Clinical trials for Coronary Artery Disease

Does Montelukast Have an Affect on the Function of the Artery in Patients With Heart Disease

Start date: July 2006
Phase: Phase 4
Study type: Interventional

To evaluate the effect of the drug Montelukast on the brachial artery's function. By giving a drug like Montelukast, which blocks the effects of inflammation in the lungs arteries and controls asthma, we hope to see positive effects in other arteries such as in the heart.

NCT ID: NCT00351325 Terminated - Clinical trials for Advanced Solid Malignancies

A Study of BMS-663513 Administered in Combination With Chemotherapy to Subjects With Advanced Solid Malignancies

Start date: September 2007
Phase: Phase 1
Study type: Interventional

The purpose of this study is to assess the safety and tolerability of multiple escalating doses of BMS-663513 when given in combination with paclitaxel and carboplatin.

NCT ID: NCT00350688 Terminated - Bladder Cancer Clinical Trials

Bladder Cancer Chemoradiation Using Intensity Modulated Radiation Therapy

Start date: November 2005
Phase: N/A
Study type: Interventional

While the gold standard of treatment in invasive bladder cancer is surgical removal of the bladder, it is well accepted that a reasonable alternative is an organ preserving approach. Bladder preservation can be achieved in patients with radiotherapy alone or together with concurrent chemotherapy. This clinical trial will assess the potential of intensity modulated radiation therapy (IMRT) delivered using helical tomotherapy to reduce radiation-induced gastrointestinal toxicity and increase the accuracy of bladder cancer irradiation.

NCT ID: NCT00349752 Terminated - Crohn's Disease Clinical Trials

Corticosteroid Sparing Effect of Certolizumab in Crohn's Disease

COSPAR1
Start date: November 2006
Phase: Phase 3
Study type: Interventional

The current study is designed to measure the corticosteroid-sparing effect of certolizumab pegol using a defined schedule of corticosteroid tapering in subjects with moderate to severe Crohn's disease. Subjects had to be in remission (CDAI<=150) and receiving corticosteroids at a dose no higher than 30 mg/day prednisone or equivalent during the week prior to randomization.

NCT ID: NCT00348894 Terminated - Pain Clinical Trials

[S,S]-Reboxetine Long Term Safety Study In Chronic Painful Diabetic Peripheral Neuropathy.

Start date: July 2006
Phase: Phase 2
Study type: Interventional

The purpose of this study is to assess the long-term safety and tolerability of [S,S]-Reboxetine in patients with chronic painful diabetic peripheral neuropathy